Diabetes
News from the FDA/CDC
FDA approves first-ever agent to delay type 1 diabetes onset
Teplizumab delayed progression to clinical type 1 diabetes by about 2 years compared with placebo in individuals destined to develop the condition...
Commentary
New recommendations for hyperglycemia management
These are incredibly important guidelines that provide a clear algorithm for a personalized approach to diabetes management.
Feature
Patients complain some obesity care startups offer pills, and not much else
A wave of startups offer access to a new category of weight-loss drugs coupled with intensive behavioral coaching online. But already concerns are...
From the Journals
‘Key cause’ of type 2 diabetes identified
“This suggests a potential way in which the decline in beta-cell function in T2D might be slowed or prevented.”
Conference Coverage
Statins boost glycemia slightly, but CVD benefits prevail
Meta-analysis of 23 trials confirmed statins raise glycemia and can trigger diabetes, but the effect pales compared with their CVD prevention.
From the Journals
Has the time come for glucose monitors for people without diabetes?
The increasing popularity of continuous glucose monitoring devices in prediabetes and for ‘wellness’ prompts discussion about appropriate use and...
Conference Coverage
New dual-agonist weight-loss injection impressive, but early days
The “bottom line” is that this potential new antiobesity/diabetes drug is “very promising, but [it is] still a little early to say where it...
Conference Coverage
Tirzepatide lowers weight across all groups with obesity
The antiobesity medication semaglutide “took things up one big notch, and now tirzepatide is up a little notch above that,” one expert said.
Conference Coverage
If a saphenous graft is available, treat limb threatening ischemia surgically
Surgery beats endovascular treatment for limb threatening ischemia when saphenous grafts are an option, according to the BEST-CLI trial.
Conference Coverage
NAFLD patients with diabetes have higher fibrosis progression rate
Patients with type 2 diabetes had about a 2-year faster progression to fibrosis.
Conference Coverage
Triglyceride-lowering fails to show CV benefit in large fibrate trial
In the phase 3 PROMINENT trial, pemafibrate improved multiple lipid fractions in patients with type 2 diabetes, without any impact on...